Cantor Fitzgerald Weighs in on Immunocore Holdings plc’s FY2023 Earnings (NASDAQ:IMCR)

Immunocore Holdings plc (NASDAQ:IMCR) – Research analysts at Cantor Fitzgerald issued their FY2023 EPS estimates for Immunocore in a report issued on Thursday, November 2nd. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will earn ($1.74) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($1.34) per share. Cantor Fitzgerald also issued estimates for Immunocore’s FY2024 earnings at ($2.28) EPS.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Thursday, August 10th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.03. The firm had revenue of $60.70 million during the quarter, compared to analysts’ expectations of $59.39 million. Immunocore had a negative net margin of 27.72% and a negative return on equity of 17.97%.

Several other research firms also recently issued reports on IMCR. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Immunocore in a research note on Wednesday, August 23rd. BTIG Research upped their price objective on Immunocore from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Friday, August 11th. Morgan Stanley reaffirmed an “overweight” rating and issued a $79.00 price objective on shares of Immunocore in a research note on Monday, July 31st. Canaccord Genuity Group assumed coverage on Immunocore in a research note on Monday, July 17th. They issued a “hold” rating and a $67.00 price objective for the company. Finally, Robert W. Baird assumed coverage on Immunocore in a research note on Tuesday, October 31st. They issued an “outperform” rating and a $84.00 price objective for the company. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $72.29.

Immunocore Stock Up 5.6 %

IMCR stock opened at $49.15 on Monday. The stock has a market capitalization of $2.41 billion, a P/E ratio of -38.10 and a beta of 0.75. The company has a current ratio of 4.28, a quick ratio of 4.26 and a debt-to-equity ratio of 0.23. Immunocore has a 12 month low of $42.21 and a 12 month high of $69.06. The firm has a 50-day moving average price of $50.60 and a 200-day moving average price of $56.69.

Institutional Trading of Immunocore

Several large investors have recently modified their holdings of IMCR. Virtu Financial LLC bought a new position in shares of Immunocore in the 1st quarter worth $496,000. Oppenheimer Asset Management Inc. bought a new position in shares of Immunocore in the 2nd quarter worth $355,000. Wellington Management Group LLP lifted its holdings in shares of Immunocore by 56.8% in the 1st quarter. Wellington Management Group LLP now owns 3,375,309 shares of the company’s stock worth $166,875,000 after purchasing an additional 1,222,343 shares in the last quarter. Exchange Traded Concepts LLC bought a new position in shares of Immunocore in the 2nd quarter worth $148,000. Finally, Brown Advisory Inc. bought a new position in shares of Immunocore in the 2nd quarter worth $240,000. Institutional investors and hedge funds own 73.45% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers.